Psychedelic Morning News Brief — October 5, 2026
1. Psilocybin & LSD Advance Toward FDA Approval
Synopsis: New Psychology Today overview examines the progress of Psilocybin & LSD through late-stage trials. It highlights reported positive Phase 3 results for treatment-resistant depression & generalized anxiety disorder, while emphasizing that company announcements aren’t FDA approval.
My take: There’s real progress here, & demanding good evidence doesn’t make someone anti-Psychedelic. However, I am becoming increasingly convinced Psychedelic culture will remain underground.
2. DEA Revives Proposal to Ban 5 Psychedelic Compounds
Synopsis: The DEA has renewed its proposal to place 5 Psychedelic tryptamines into Schedule I, after withdrawing an earlier attempt in 2022. In a 9/30 statement, Students for Sensible Drug Policy warned that the restrictions could impede research, highlighting that one targeted compound, 4-OH-DiPT, is the substance released by an investigational drug being developed for postpartum depression. The proposal hasn’t been finalized.
My take: This is some bullshit. We’re celebrating the medical potential of Psychedelics while still reaching for prohibition on compounds we’re trying to understand. A drug doesn’t need to become an FDA-approved medicine to justify its existence. If the government wants to criminalize it, the burden should be demonstrating why that intervention is necessary.
3. Who Gets to Provide Psychedelic Therapy?
Synopsis: An October 1 report from the Congressional Psychedelics Advancing Therapies Caucus recommends multiple pathways for qualifying therapy providers, national consent & screening standards, & a system to monitor adverse events.
My take: Who gets to provide these treatments will shape who can afford them. Requirements should establish actual competence: screening, consent, boundaries & knowing what to do when something goes wrong. I want meaningful standards, & I want every expensive credential justified by what it does for the person receiving care.
